FDA Grants Breakthrough Therapy Designation for AOC 1001 in Myotonic Dystrophy Type 1
Sarah Boyce(Credit: Avidity)According to a recent announcement, the FDA has granted breakthrough therapy designation to AOC 1001 (Avidity Biosciences), an investigational treatment...
Alkermes Initiates Phase 2 Vibrance-1 Trial of Narcolepsy Agent ALKS 2680
Craig Hopkinson, MD(Credit: LinkedIn)According to a recent announcement, Alkermes has initiated its randomized, double-blind, dose-range-finding, placebo-controlled phase 2 Vibranc...
Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim
In a randomized, placebo-controlled trial, bezisterim (BioVie), an oral, small molecule, blood-brain permeable compound in development for Alzheimer disease (AD), demonstrated pote...
